IQVIA Holdings Inc. (NYSE:IQV) Position Increased by Candriam S.C.A.

Candriam S.C.A. lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 35.5% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 389,152 shares of the medical research company’s stock after buying an additional 102,031 shares during the quarter. Candriam S.C.A. owned approximately 0.21% of IQVIA worth $82,278,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of IQV. Lazard Asset Management LLC lifted its holdings in IQVIA by 0.9% in the first quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock worth $825,416,000 after acquiring an additional 30,014 shares during the last quarter. Canada Pension Plan Investment Board boosted its position in IQVIA by 6.4% during the 1st quarter. Canada Pension Plan Investment Board now owns 3,191,835 shares of the medical research company’s stock valued at $807,183,000 after purchasing an additional 193,304 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in IQVIA by 3.8% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock worth $634,927,000 after buying an additional 92,293 shares during the last quarter. Capital Research Global Investors increased its position in IQVIA by 7.2% in the first quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock worth $540,882,000 after buying an additional 143,533 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in IQVIA by 339.6% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock valued at $478,308,000 after buying an additional 1,597,003 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

NYSE:IQV opened at $243.10 on Friday. The company has a 50-day moving average of $234.92 and a 200-day moving average of $234.63. The firm has a market cap of $44.29 billion, a price-to-earnings ratio of 33.21, a price-to-earnings-growth ratio of 2.37 and a beta of 1.49. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73.

IQVIA (NYSE:IQV) last issued its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. During the same period last year, the firm posted $2.22 earnings per share. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. Analysts forecast that IQVIA Holdings Inc. will post 10.24 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Thursday. Evercore ISI raised their price target on shares of IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. The Goldman Sachs Group assumed coverage on IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 price target on the stock. Truist Financial increased their price objective on IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Finally, UBS Group boosted their price target on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $266.67.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.